Hydractinia RNA as a Research Tool
Search text
Diagnostic/Assay
About 5 results
(0.06 seconds)
RNA- and DNA-Based Assays for Predicting Paclitaxel Resistance in Triple Negative Breast Cancer
05224
RNA- and DNA-based assays for this gene fusion can be used to predict paclitaxel resistance in triple negative breast cancer and allow treatment providers to quickly pivot to alternative treatment options, sparing the patient from the unnecessary and unpleasant side effects of chemotherapy, in addition to serving as a target for novel therapeutics. Recent genomic sequencing studies have revealed a lack of TNBC-specific mutations. While the complexity of genomic rearrangements in this cancer has obscured the role that gene fusions play in the pathology of TNBC, researchers at the University of Pittsburgh identified 99 recurrent gene fusions, 57% of which are cryptic adjacent gene rearrangements (AGRs).
Identification of EBV within patient samples is quantified using EBV RNA and is used to diagnose EBV cancers. Presented is a diagnostic tool that can accurately and rapidly identify EBV infections and EBV cancers developed using unique EBV circular RNAs, called circBARTs, which are easily extracted and measured from patient tissue samples using an accessible, low-cost, and rapid method of detection. These circBARTs were reliably detected across several types of EBV-positive tumors and were even detected in two patient samples falsely deemed to be EBV-negative through the detection of an older, more fragile EBV RNA biomarker.
Targeting Highly Tumor-specific Long Non-coding RNAs for Cancer Diagnosis, Prognosis, and Therapy
04518
Long non-coding RNAs (lncRNAs) are genetic regulatory molecules associated with cancer occurrence and progression, representing attractive therapeutic targets for cancer therapy. Researchers paired the detection of these lncRNAs with genetic and clinical data from 1,023 breast tumor samples and 24 breast cancer cell lines.